Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results

Core Viewpoint - Clearmind Medicine Inc. is advancing its clinical trial for CMND-100, a non-hallucinogenic treatment for Alcohol Use Disorder (AUD), following positive results from previous cohorts [1][2][4]. Group 1: Clinical Trial Progress - The company is continuing participant enrollment for the third cohort of its FDA-approved Phase I/IIa clinical trial for CMND-100 [1]. - The second cohort's results showed continued safety and tolerability, leading to unanimous approval from the Data and Safety Monitoring Board (DSMB) to proceed with the next phase [2]. - The trial is a multinational, multicenter study aimed at evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD [3]. Group 2: Company Insights - Clearmind Medicine focuses on developing novel, non-hallucinogenic therapeutics derived from neuroplastogens to address significant health issues, including AUD [5]. - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [6].